Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

Journal of Cellular Physiology

Volumn 205, Issue 3, 2005, Pages 355-363

  Di Maio, Massimo ^a   Gridelli, Cesare ^b   Normanno, Nicola ^a   Perrone, Francesco ^a   Ciardiello, Fortunato ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; TOPOTECAN; TRANSFORMING GROWTH FACTOR ALPHA;

APOPTOSIS; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; GENDER; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; SMOKING; SOMATIC MUTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; METAPHOR; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 27744534956     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20402     Document Type: Article

References (76)

1. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, Averbuch S, Baselga J. 2003. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9:1274-1283.
2. Arteaga C. 2004. EGFR mutations predict response to gefitinib-now what? 2004 ASCO Annual Meeting-Education Program (available on-line at http:// www.asco.org/ac/1,1003,12-002511-00 18-0026-00 19-0011619,00.asp; accessed February 8th, 2005).
3. Arteaga CL, Baselga J. 2003. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practice. Clin Cancer Res 9:1579-1589.
4. Arteaga CL, Baselga J. 2004. Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? Cancer Cell 5:525-531.
5. Bailey LR, Janas M, Schmidt K, Bindslev N, Wolf M, Grous J, Askaa J, Herbst R, Johnson DH, Giaccone G. 2004. Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004:7013.
6. Baselga J. 2004. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? J Clin Oncol 22:759-761.
7. Betensky RA, Louis DN, Cairncross JG. 2002. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-2499.
8. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV. 2001. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855.
9. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Vigano L, Fumagalli M, Menard S, Gianni L. 2004. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 198:259-268.
10. Cappuzzo F, Gregore V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E, Crino L. 2003. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21:2658-2663.
11. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregore V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crino L. 2004. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96:1133-1141.
12. Ciardiello F, Tortora G. 2002. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Invest Drugs 11:755-768.
13. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AH, Tortora G. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063.
14. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G. 2001. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465.
15. Ciardiello F, De Vita F, Orditura M, Tortora G. 2004. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 16:130-135.
16. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD, Jr., Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R. 2004. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res.10:1212-1218.
17. Eisenhauer EA. 1998. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann Oncol 9:1047-1052.
18. Franke TF, Kaplan DR, Cantley LC. 1997. PI3K: Downstream AKTion blocks apoptosis. Cell 91:231-241.
19. Freidlin B, Breathnach OS, Johnson BE. 2003. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 9:917-922.
20. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246.
21. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F, Mueller B, Von Pawel J, for the TALENT Study Investigators. 2004. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004:7010.
22. Gazdar AF, Shigematsu H, Herz J, Minna JD. 2004. Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers? Trends Mol Med 10:481-486.
23. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Resell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22:777-784.
24. Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, van Zandwijk N, Di Maio M, Martelli O, De Marinis F. 2004. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: Results of an European Experts Panel. Ann Oncol 15:419-426.
25. Gridelli C, Aapro M, Ardizzoni A, Balducci L, De Marinis F, Kelly K, Le Chevalier T, Manegold C, Perrone F, Rosell R, Shepherd F, De Petris L, Di Maio M, Langer C. 2005. Treatment of advanced non-small-cell lung cancer in the elderly: Results of an International Expert Panel. J Clin Oncol (in press).
26. Grunwald V, Hidalgo M. 2003. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95:851-867.
27. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK. 2005. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with Gefitinib. J Clin Oncol Feb 14 [Epub ahead of print].
28. Herbst RS, Giaccone G, Schiller JH, Miller V, Natale R, Rennie P, Ochs J, Fandi A, Grous J, Johnson D. 2003. Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy for advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 22:627 (abstr 2523).
29. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. 2004a. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22:785-794.
30. Herbst RS, Prager D, Hermann R, Miller V, Fehrenbacher L, Huffman P, Johnson B, Sandler AB, Mass R, Johnson DH. 2004. TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004:7011.
31. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF. 2004. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203.
32. Janmaat ML, Kruyt FAE, Rodriguez JA, Giaccone G. 2003. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9:2316-2326.
33. Johnson BE, Lucca J, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, Liu G, Janne PA. 2004. A phase II trial of erlotinib in previously untreated elderly patients (> = 70 years) with advanced NSCLC. Preliminary results. Ann Oncol 15(suppl 3)
34. Abstract Book of the 29th ESMO Congress, Vienna, Austria, 29 October-2 November 2004, iii169 (Abstr 639PD).
35. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. 2001. Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272.
36. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. 2004. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923.
37. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158.
38. Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, Hittelman WN, Yu R, Lee JJ, Hong WK. 1996. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2:1787-1793.
39. Lewis TS, Shapiro PS, Ahn NG. 1998. Signal transduction through MAP kinase cascade. Adv Cancer Res 74:49-139.
40. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. 2004. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. N Engl J Med 350:2129-2139.
41. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Camplese PP, Iarussi T, Mucilli F, Mazzetti A, Cuccurullo F, Sacco R, Buttitta F. 2005. EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential therapeutic implications on pharmacologic treatment. J Clin Oncol 23:857-865.
42. Mendelsohn J. 2002. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20(18 Suppl):1S-13S.
43. Mendelsohn J, Baselga J. 2003. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799.
44. Miller VA, Patel J, Shah N, Kris MG, Tyson L, Pizzo B, Zakowski M, Memoli N, Sandler A, Johnson DH. 2003. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): Preliminary results of a phase II trial. Proc Am Soc Clin Oncol 22:619. 2003 (abstr 2491).
45. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT. 2004a. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109.
46. Miller VA, Herbst R, Prager D, Fehrenbacher L, Hermann R, Hoffman P, Johnson B, Sandler AB, Kris MG, Ramies D. 2004b. Long survival of never smoking non-small cell lung cancer patients treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vo 22, No 14S (July 15 Supplement), 2004: 7061.
47. Moasser MM, Basso A, Averbuch SD, Rosen N. 2001. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188.
48. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. 2001. Epidermal growth factor receptor (HERD tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895.
49. Normanno N. 2005. Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: Simply a bad combination? J Clin Oncol 23:928-930.
50. Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S. 2002. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65-72.
51. Normanno N, Maiello MR, De Luca A. 2003a. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action? J Cell Physiol 194:13-19.
52. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. 2003b. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 10:1-21.
53. Normanno N, Di Maio M, Perrone F, Campiglio M. 2004. Molecular markers to predict response to gefitinib: EGFR, Erb-B2, or more? J Clin Oncol 22:2035-2036.
54. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
55. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. 2004a. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311.
56. Pao W, Miller VA, Venkatraman E, Kris MG. 2004b. Predicting sensitivity of non-small-cell lung cancer to gefitinib: Is there a role for P-Akt? J Natl Cancer Inst 96:1117-1119.
57. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. 2005. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(l):e17. (Epub 2005 Jan 25).
58. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. 2004a. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247.
59. Perez-Soler R, Piperdi B, Haigentz M, Ling YH. 2004b. Determinants of sensitivity to the EGFR TK inhibitor erlotinib (E) in a panel of NSCLC cell lines. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7026.
60. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Jr., Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. 2004. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353.
61. Piperdi B, Ling YH, Kroog G, Perez-Soler R. 2004. Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7028.
62. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. 1997. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515-522.
63. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 9:183-232.
64. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Eastern Cooperative Oncology Group. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98.
65. Seymour L. 2002. The design of clinical trials for new molecularly targeted compounds: Progress and new initiatives. Curr Pharm Des 8:2279-2284.
66. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA. 2005. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23:165-174.
67. nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7022.
68. Sirotnak FM. 2003. Studies with ZD1839 in preclinical models. Semin Oncol 30(1 Suppl 1):12-20.
69. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. 2000. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 dressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892.
70. Sordella R, Bell DW, Haber DA, Settleman J. 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167.
71. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar AF, Shimizu N. 2005. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167-1173.
72. Tracy S, Mukuoka T, Hansen M, Meyersen M, Johnson BE, Janne PA. 2004. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 64:7241-7244.
73. Ullrich A, Schlessinger J. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212.
74. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. 1993. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68:162-165.
75. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726.
76. Volm M, Koomagi R, Mattern J, Efferth T. 2002. Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res 8:1843-1848.